Zurcher Kantonalbank Zurich Cantonalbank Has $10.44 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Zurcher Kantonalbank Zurich Cantonalbank lowered its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 14.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,123 shares of the biotechnology company's stock after selling 4,820 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.07% of United Therapeutics worth $10,436,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. B. Riley Wealth Advisors Inc. bought a new stake in shares of United Therapeutics during the 1st quarter worth $219,000. Cetera Advisors LLC acquired a new position in shares of United Therapeutics in the 1st quarter valued at $475,000. GAMMA Investing LLC increased its stake in United Therapeutics by 84.8% in the 2nd quarter. GAMMA Investing LLC now owns 390 shares of the biotechnology company's stock worth $124,000 after purchasing an additional 179 shares in the last quarter. DNB Asset Management AS raised its holdings in United Therapeutics by 18.3% during the 2nd quarter. DNB Asset Management AS now owns 7,800 shares of the biotechnology company's stock worth $2,485,000 after buying an additional 1,208 shares during the period. Finally, Park Avenue Securities LLC lifted its stake in United Therapeutics by 30.4% during the second quarter. Park Avenue Securities LLC now owns 2,037 shares of the biotechnology company's stock valued at $649,000 after buying an additional 475 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Down 0.1 %

NASDAQ UTHR traded down $0.37 during trading on Monday, hitting $370.12. The company's stock had a trading volume of 315,271 shares, compared to its average volume of 456,115. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The firm has a market cap of $16.53 billion, a P/E ratio of 16.27, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56. The firm has a 50 day moving average price of $367.77 and a 200 day moving average price of $336.09.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analysts' expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business's quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the company earned $5.38 EPS. On average, equities analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on UTHR shares. Wells Fargo & Company upped their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a research report on Tuesday, August 20th. Oppenheimer increased their target price on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. HC Wainwright raised their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. TD Cowen upped their price target on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Finally, StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $370.86.

Insider Activity at United Therapeutics

In other news, Director Nilda Mesa sold 224 shares of the firm's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $412.28, for a total transaction of $92,350.72. Following the completion of the transaction, the director now directly owns 5,783 shares of the company's stock, valued at approximately $2,384,215.24. This trade represents a 3.73 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $960,576.75. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 127,227 shares of company stock worth $47,398,820. Company insiders own 11.90% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.